Beam Therapeutics
Logotype for Beam Therapeutics Inc

Beam Therapeutics (BEAM) investor relations material

Beam Therapeutics Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Beam Therapeutics Inc
Jefferies Global Healthcare Conference summary18 Nov, 2026

BEAM-302 and alpha-1 antitrypsin deficiency

  • BEAM-302 is in a pivotal accelerated-approval cohort; enrollment is swift, with the 50th dose expected in H1 2027, followed by 12 months of follow-up and a filing package.

  • Trial spans six countries and 15+ enrolling sites; screen failures are low and predictable, with similar recruitment rates in the U.S. and ex-U.S.

  • The intended pivotal population includes patients with lung disease, with or without liver involvement; more than 90% of patients fall within this broad label.

  • Reported data showed 90%+ corrected M protein, reduced Z protein and inducible expression; one infection case showed AAT rising from the mid-teens to 25 micromolar.

  • Additional updates are expected to include liver biopsies, BAL fluid, CT densitometry, FEV1 and patient-reported outcomes; no interim disclosure is planned for the 50-patient pivotal cohort.

Regulatory path and competitive position

  • FDA feedback calls for 12 months of pivotal follow-up; earlier engagement could be considered if data show a robust, stable benefit, but the current plan remains a 12-month dataset.

  • CT densitometry is the preferred confirmatory endpoint; SPARTA results expected by year-end 2026 may inform its use, while FEV1 and St. George's Respiratory Questionnaire remain alternatives.

  • Management described a multi-year lead in alpha-1 clinical experience and plans to build payer and site relationships; LNP delivery is viewed as scalable for broad treatment after launch.

Risto-cel and sickle cell opportunity

  • Risto-cel BLA writing is being finalized, with filing on track for December 2026; approval could come in Q3 2027 with Priority Review or December 2027 under standard review.

  • Management cited projected 2026 sales above $700M for the two marketed sickle cell gene therapies and forecast a $1B+ category starting in 2027.

  • Risto-cel differentiation includes 60% fetal hemoglobin and 40% sickle hemoglobin, faster engraftment by several days, full anemia resolution and median single-round mobilization in BEACON.

  • Commercial preparation includes patient-journey tracking, hospital coordination and a modest field footprint focused on large U.S. centers.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Beam Therapeutics earnings date

Logotype for Beam Therapeutics Inc
9th Annual Evercore ISI HealthCONx Conference2 Dec, 2026
Beam Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Beam Therapeutics earnings date

Logotype for Beam Therapeutics Inc
9th Annual Evercore ISI HealthCONx Conference2 Dec, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Beam Therapeutics Inc is a biotechnology company focused on the development of precision genetic medicines using base editing technology. The company’s approach aims to correct genetic mutations at the single-base level to treat various diseases, including genetic disorders and cancers. It conducts research and development in-house and through collaborations. Beam Therapeutics Inc is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.